Tissue Archiving May Preclude Prospective Data In Deciding Assay Utility
This article was originally published in The Gray Sheet
Executive Summary
Drug companies anticipating use of molecular assays to complement therapies under development could be encouraged to rely on tissue-banked specimen analyses in lieu of prospective, randomized trials demonstrating clinical utility
You may also be interested in...
NCI-FDA Panel Will Publish Draft Guidelines On Cancer Assay Development
FDA Division of Clinical Laboratory Devices Director Steve Gutman is serving on a National Cancer Institute panel that will issue draft guidelines on cancer marker and assay development and publication of studies by early 2002
NCI-FDA Panel Will Publish Draft Guidelines On Cancer Assay Development
FDA Division of Clinical Laboratory Devices Director Steve Gutman is serving on a National Cancer Institute panel that will issue draft guidelines on cancer marker and assay development and publication of studies by early 2002
Abbott/Vysis’ PathVysion HER-2 Assay Endorsed By Herceptin Panel Review
Genentech's Herceptin package insert to include use of Vysis' PathVysion fluorescence in situ hybridization (FISH) test should address potential discrepancies in assay results compared with immunohistochemistry (IHC) tests, FDA's Oncologic Drugs Advisory Committee concluded